SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP announces it has commenced an investigation of Sunesis Pharmaceuticals Inc. (“Sunesis”) (NASDAQ: SNSS) concerning possible violations of federal securities laws.

The investigation concerns whether the Company and its executives violated federal securities laws by failing to appropriately disclose the suitability of the Company's treatment vosaroxin for approval in Europe. Specifically, on May 2, 2017, Sunesis announced that the Company will withdraw its European Marketing Authorization Application for vosaroxin, following recent interactions with the European Medicine Agency's Committee for Medicinal Products for Human Use. Sunesis announced that it had learned that the committee was likely to formally adopt a negative opinion in its evaluation of the product, leading to its withdrawal. To obtain additional information, go to:

http://zlk.9nl.com/sunesis-snss

or contact Joseph E. Levi, Esq. either via email at [e-mail] or by telephone at [phone], toll-free: [phone].

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.